Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2024-11-07
- Target Recruit Count
- 110
- Registration Number
- NCT03252938
- Locations
- 🇩🇪
Universitätsklinikum Essen, Essen, Germany
🇩🇪Agaplesion Markus Krankenhaus Frankfurter Diakonie Kliniken gGmbH, Frankfurt, Germany
🇩🇪Universität Gießen und Marburg GmbH, Gießen, Germany
Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study
- Conditions
- Interventions
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Austin Health
- Target Recruit Count
- 28
- Registration Number
- NCT03244176
- Locations
- 🇦🇺
Ballarat Health, Ballarat, Victoria, Australia
🇦🇺Austin Health, Heidelberg, Victoria, Australia
🇦🇺Eastern Health, Box Hill, Victoria, Australia
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
- Conditions
- Advanced Malignant Solid NeoplasmCastration-Resistant Prostate CarcinomaMalignant Solid NeoplasmMetastatic Malignant Solid NeoplasmMetastatic Prostate CarcinomaProstate Carcinoma Metastatic in the BoneRefractory Malignant Solid NeoplasmStage IV Prostate Cancer AJCC V8Stage IVA Prostate Cancer AJCC V8Stage IVB Prostate Cancer AJCC V8
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 173
- Registration Number
- NCT03217747
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 12
- Registration Number
- NCT03200587
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 132
- Registration Number
- NCT03186326
- Locations
- 🇫🇷
Ch - Centre Hospitalier Intercommunal, Villeneuve-Saint-Georges, France
🇫🇷Ch - Centre Hospitalier Du Pays D'Aix, Aix-en-Provence, France
🇫🇷Privé - Institut Sainte Catherine, Avignon CEDEX, France
PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Andrew J. Armstrong, MD
- Target Recruit Count
- 15
- Registration Number
- NCT03179410
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 43
- Registration Number
- NCT03174405
- Locations
- 🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Megan Daly, MD
- Target Recruit Count
- 8
- Registration Number
- NCT03158883
- Locations
- 🇺🇸
UC Davis, Sacramento, California, United States
Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2020-10-06
- Target Recruit Count
- 28
- Registration Number
- NCT03152565
- Locations
- 🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇪🇸Hospital Universitario y Politécnico La Fe, Valencia, Spain
🇪🇸Hospital Clínic Barcelona, Barcelona, Spain
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT03150706
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.